S&P 500   3,276.24 (+1.01%)
DOW   28,722.85 (+0.66%)
QQQ   221.45 (+1.54%)
AAPL   317.69 (+2.83%)
FB   217.79 (+1.36%)
MSFT   165.46 (+1.96%)
GOOGL   1,450.50 (+1.31%)
AMZN   1,853.25 (+1.36%)
CGC   23.92 (+10.95%)
NVDA   247.97 (+3.23%)
BABA   210.23 (+2.32%)
MU   56.47 (+1.91%)
GE   11.73 (+2.53%)
TSLA   566.90 (+1.59%)
AMD   50.53 (+2.58%)
T   38.58 (+0.86%)
ACB   1.97 (+4.23%)
F   8.97 (+0.90%)
NFLX   348.52 (+1.64%)
PRI   120.64 (+1.31%)
BAC   33.24 (+1.19%)
DIS   138.37 (+1.82%)
GILD   64.36 (+0.83%)
S&P 500   3,276.24 (+1.01%)
DOW   28,722.85 (+0.66%)
QQQ   221.45 (+1.54%)
AAPL   317.69 (+2.83%)
FB   217.79 (+1.36%)
MSFT   165.46 (+1.96%)
GOOGL   1,450.50 (+1.31%)
AMZN   1,853.25 (+1.36%)
CGC   23.92 (+10.95%)
NVDA   247.97 (+3.23%)
BABA   210.23 (+2.32%)
MU   56.47 (+1.91%)
GE   11.73 (+2.53%)
TSLA   566.90 (+1.59%)
AMD   50.53 (+2.58%)
T   38.58 (+0.86%)
ACB   1.97 (+4.23%)
F   8.97 (+0.90%)
NFLX   348.52 (+1.64%)
PRI   120.64 (+1.31%)
BAC   33.24 (+1.19%)
DIS   138.37 (+1.82%)
GILD   64.36 (+0.83%)
S&P 500   3,276.24 (+1.01%)
DOW   28,722.85 (+0.66%)
QQQ   221.45 (+1.54%)
AAPL   317.69 (+2.83%)
FB   217.79 (+1.36%)
MSFT   165.46 (+1.96%)
GOOGL   1,450.50 (+1.31%)
AMZN   1,853.25 (+1.36%)
CGC   23.92 (+10.95%)
NVDA   247.97 (+3.23%)
BABA   210.23 (+2.32%)
MU   56.47 (+1.91%)
GE   11.73 (+2.53%)
TSLA   566.90 (+1.59%)
AMD   50.53 (+2.58%)
T   38.58 (+0.86%)
ACB   1.97 (+4.23%)
F   8.97 (+0.90%)
NFLX   348.52 (+1.64%)
PRI   120.64 (+1.31%)
BAC   33.24 (+1.19%)
DIS   138.37 (+1.82%)
GILD   64.36 (+0.83%)
S&P 500   3,276.24 (+1.01%)
DOW   28,722.85 (+0.66%)
QQQ   221.45 (+1.54%)
AAPL   317.69 (+2.83%)
FB   217.79 (+1.36%)
MSFT   165.46 (+1.96%)
GOOGL   1,450.50 (+1.31%)
AMZN   1,853.25 (+1.36%)
CGC   23.92 (+10.95%)
NVDA   247.97 (+3.23%)
BABA   210.23 (+2.32%)
MU   56.47 (+1.91%)
GE   11.73 (+2.53%)
TSLA   566.90 (+1.59%)
AMD   50.53 (+2.58%)
T   38.58 (+0.86%)
ACB   1.97 (+4.23%)
F   8.97 (+0.90%)
NFLX   348.52 (+1.64%)
PRI   120.64 (+1.31%)
BAC   33.24 (+1.19%)
DIS   138.37 (+1.82%)
GILD   64.36 (+0.83%)
Log in

OTCMKTS:ENOB - Enochian Biosciences Stock Price, Forecast & News

$4.65
-0.63 (-11.93 %)
(As of 01/28/2020 04:00 PM ET)
Today's Range
$4.63
Now: $4.65
$5.29
50-Day Range
$4.18
MA: $5.24
$6.53
52-Week Range
$2.91
Now: $4.65
$8.75
Volume46,608 shs
Average Volume61,000 shs
Market Capitalization$215.17 million
P/E RatioN/A
Dividend YieldN/A
BetaN/A
Enochian Biosciences Inc., a biopharmaceutical company, identifies, develops, manufactures, and commercializes gene therapies for HIV/AIDS and cancer patients. Its lead candidate include ENO-1001 a genetically modified cell therapy for patients with HIV/AIDS. It is also developing ENO-2001, an HIV vaccine; and additional compounds, such as ENO-4001, ENO-4002, ENO-3001, and ENO-5001 that are in discovery stage for prevention of relapse in colon cancer patients. Enochian BioSciences is headquartered in Los Angeles, California.

Industry, Sector and Symbol

Industry Biotechnology
Sub-IndustryN/A
SectorMedical
Current SymbolOTCMKTS:ENOB
CUSIPN/A
CIKN/A
Phone510-203-4857

Debt

Price-To-Earnings

Sales & Book Value

Annual SalesN/A

Profitability

Miscellaneous

EmployeesN/A
Market Cap$215.17 million
Next Earnings DateN/A
OptionableNot Optionable

Receive ENOB News and Ratings via Email

Sign-up to receive the latest news and ratings for ENOB and its competitors with MarketBeat's FREE daily newsletter.


Enochian Biosciences (OTCMKTS:ENOB) Frequently Asked Questions

What is Enochian Biosciences' stock symbol?

Enochian Biosciences trades on the OTCMKTS under the ticker symbol "ENOB."

How were Enochian Biosciences' earnings last quarter?

Enochian Biosciences Inc (OTCMKTS:ENOB) posted its quarterly earnings results on Wednesday, November, 13th. The company reported ($0.09) earnings per share for the quarter. View Enochian Biosciences' Earnings History.

Has Enochian Biosciences been receiving favorable news coverage?

News stories about ENOB stock have been trending somewhat negative recently, InfoTrie reports. The research firm identifies positive and negative press coverage by analyzing more than six thousand news and blog sources. The firm ranks coverage of public companies on a scale of -5 to 5, with scores nearest to five being the most favorable. Enochian Biosciences earned a daily sentiment score of -1.0 on InfoTrie's scale. They also assigned headlines about the company a news buzz of 0.0 out of 10, meaning that recent press coverage is extremely unlikely to have an effect on the company's share price in the near term. View News Stories for Enochian Biosciences.

Who are some of Enochian Biosciences' key competitors?

What other stocks do shareholders of Enochian Biosciences own?

How do I buy shares of Enochian Biosciences?

Shares of ENOB can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity and Charles Schwab.

What is Enochian Biosciences' stock price today?

One share of ENOB stock can currently be purchased for approximately $4.65.

How big of a company is Enochian Biosciences?

Enochian Biosciences has a market capitalization of $215.17 million. View Additional Information About Enochian Biosciences.

What is Enochian Biosciences' official website?

The official website for Enochian Biosciences is http://www.enochianbio.com/.

How can I contact Enochian Biosciences?

The company can be reached via phone at 510-203-4857.


MarketBeat Community Rating for Enochian Biosciences (OTCMKTS ENOB)

Community Ranking:  2.6 out of 5 (star star)
Outperform Votes:  22 (Vote Outperform)
Underperform Votes:  20 (Vote Underperform)
Total Votes:  42
MarketBeat's community ratings are surveys of what our community members think about Enochian Biosciences and other stocks. Vote "Outperform" if you believe ENOB will outperform the S&P 500 over the long term. Vote "Underperform" if you believe ENOB will underperform the S&P 500 over the long term. You may vote once every thirty days.
This page was last updated on 1/28/2020 by MarketBeat.com Staff

Enter your email address below to receive a concise daily summary of analysts' upgrades, downgrades and new coverage with MarketBeat.com's FREE daily email newsletter.

Yahoo Gemini Pixel